Board Change • May 29
High number of new and inexperienced directors There are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. Independent Director Elizabeth Mily is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • May 06
First quarter 2026 earnings released: EPS: US$0.075 (vs US$0.79 in 1Q 2025) First quarter 2026 results: EPS: US$0.075 (down from US$0.79 in 1Q 2025). Revenue: US$2.01b (down 3.0% from 1Q 2025). Net income: US$13.0m (down 91% from 1Q 2025). Profit margin: 0.6% (down from 6.6% in 1Q 2025). Revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. 공시 • Apr 15
Solventum Corporation to Report Q1, 2026 Results on May 05, 2026 Solventum Corporation announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 05, 2026 공시 • Mar 30
Solventum Corporation, Annual General Meeting, May 15, 2026 Solventum Corporation, Annual General Meeting, May 15, 2026. New Risk • Mar 02
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 1.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Earnings are forecast to decline by an average of 1.2% per year for the foreseeable future. Minor Risk Large one-off items impacting financial results. Reported Earnings • Feb 27
Full year 2025 earnings released: EPS: US$8.94 (vs US$2.77 in FY 2024) Full year 2025 results: EPS: US$8.94 (up from US$2.77 in FY 2024). Revenue: US$8.33b (flat on FY 2024). Net income: US$1.56b (up 225% from FY 2024). Profit margin: 19% (up from 5.8% in FY 2024). Revenue is forecast to grow 1.1% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. 공시 • Feb 04
Solventum Corporation to Report Q4, 2025 Results on Feb 26, 2026 Solventum Corporation announced that they will report Q4, 2025 results After-Market on Feb 26, 2026 공시 • Dec 18
Solventum Announces the Considers Recommendations of an International, Multidisciplinary Panel of Surgery and Wound Care experts on the Clinical Use of Closed Incision Negative Pressure Therapy with Reticulated Open Cell Foam (ROCF) Dressings Solventum announced the consensus recommendations of an international, multidisciplinary panel of surgeons and wound care experts on the clinical use of closed incision negative pressure therapy (ciNPT) with reticulated open cell foam (ROCF) dressings. The updated recommendations, appearing in the International Wound Journal, underscore the evolution of ciNPT from a long-established adjunct to incision management into a therapy that can be applied in a variety of surgical procedures that directly align with healthcare professionals' global priorities around patient safety. Solventum Prevena™? Therapy is the only ciNPT that uses ROCF dressings, a proprietary design element unique to Prevena. ciNPT is used to manage and protect surgical incisions, particularly in patients at high risk of complications. It works by applying continuous negative pressure to the incision site, helping to remove fluid and reduceension on the incision. Linear vs. area coverage: Area ciNPT dressings are preferred for complex incision geometries (e.g., intersecting or branching incisions), flap closures and sites prone to edema or lymphedema. Linear dressings remain effective for standard, high-tension incisions. Integration into protocols: ciNPT should proactively be included in SSC prevention bundles for high-risk patients and used alongside validated incision risk scoring systems. Application guidance: Hydrocolloid dressings are recommended to aid in creating a vacuum seal in difficult locations. The panel emphasized that these recommendations not only address immediate clinical needs but also lay the foundation for future guideline development. Importantly, they resonate with findings from a recent global healthcare innovation survey that identified patient safety as one of the top three priorities for medical professionals worldwide. 공시 • Nov 21
Solventum Corporation (NYSE:SOLV) announces an Equity Buyback for $1,000 million worth of its shares. Solventum Corporation (NYSE:SOLV) announces a share repurchase program. Under the program, the company will repurchase up to $1,000 million worth of its common stock. 공시 • Nov 20
Solventum Corporation (NYSE:SOLV) entered into a definitive agreement to acquire Acera Surgical, Inc. for $850 million. Solventum Corporation (NYSE:SOLV) entered into a definitive agreement to acquire Acera Surgical, Inc. for $850 million on November 20, 2025. Consideration is comprised of $725 million in cash plus up to $125 million in contingent cash payments based on the achievement of certain future milestones. The transaction is expected to be slightly dilutive to adjusted earnings per share (EPS) in 2026 and accretive to adjusted EPS beginning in 2027.Solventum plans to use its cash on hand to finance the transaction, with no additional debt or use of its credit line. Transaction is subject to customary closing conditions and is expected to complete the transaction in the first half of 2026.
Morgan Stanley & Co. LLC is serving as financial advisor and McDermott Will & Schulte LLP is acting as legal advisor to Solventum. Truist Securities, Inc. is serving as financial advisor and Hogan Lovells US LLP is acting as legal advisor to Acera. New Risk • Nov 17
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Minor Risk Large one-off items impacting financial results. Reported Earnings • Nov 09
Third quarter 2025 earnings released: EPS: US$7.26 (vs US$0.70 in 3Q 2024) Third quarter 2025 results: EPS: US$7.26 (up from US$0.70 in 3Q 2024). Revenue: US$2.10b (flat on 3Q 2024). Net income: US$1.27b (up US$1.14b from 3Q 2024). Profit margin: 60% (up from 5.9% in 3Q 2024). Revenue is forecast to stay flat during the next 3 years compared to a 5.8% growth forecast for the Medical Equipment industry in Germany. New Risk • Nov 07
New major risk - Revenue and earnings growth Earnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Earnings have declined by 21% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.5% net profit margin). 공시 • Nov 07
Solventum Corporation Increases Earnings Guidance for 2025 Solventum Corporation Increased earnings guidance for 2025. For the period the company expects Increased organic sales growth range to the high end of the +2.0% to +3.0% range (high end of the +2.5% to +3.5% excluding ~50 bps of SKU exit impact). 공시 • Oct 22
Solventum Announces Executive Changes Solventum announced the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson. Ms. Knight brings over 30 years of leadership experience in the MedTech industry. Most recently, she served as Chief Operating Officer at Baxter International, where she led global sales across three business segments, as well as R&D, supply chain, and medical and regulatory affairs. Throughout her career, Ms. Knight has held numerous roles of increasing leadership in general management, global upstream and commercial capacities at companies including Medtronic, Covidien, Tyco Healthcare and Kendall, and she currently serves on the Board of Directors of Waters Corporation. Ms. Knight earned her bachelor's degree in Biological Sciences from the University of Buffalo and completed the Executive Sales Strategy and Management program from the University of Chicago Booth School of Management. In connection with Ms. Knight's appointment, Chris Barry, Executive Vice President and Group President of MedSurg, will depart Solventum, effective December 31, 2025. 공시 • Oct 17
Solventum Corporation to Report Q3, 2025 Results on Nov 06, 2025 Solventum Corporation announced that they will report Q3, 2025 results After-Market on Nov 06, 2025 공시 • Sep 02
Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Purification Business of Solventum Corporation for approximately $4 billion. Thermo Fisher Scientific Inc. (NYSE:TMO) entered into an agreement to acquire Purification Business of Solventum Corporation for $4.1 billion on February 25, 2025. Once the transaction closes, Solventum’s Purification & Filtration business will become part of Thermo Fisher's Life Sciences Solutions segment.
The transaction is subject to regulatory approval, the expiration or termination of any required waiting periods under the Hart-Scott Rodino Antitrust Improvements Acts of 1976, as amended, the receipt of certain other applicable antitrust approvals and clearance under certain foreign investment laws, and customary closing conditions. The transaction is expected to be completed by the end of 2025.
As of June 25, 2025, Solventum and Thermo Fisher entered into an Amended and Restated Transaction Agreement, to exclude Solventum’s drinking water filtration business from the scope of the purification and filtration business and reduce the cash consideration payable for the acquired business at the closing of the transaction from approximately $4.10 billion to approximately $4.00 billion with net proceeds still intended to be used primarily to pay down debt. As of July 15, 2025 European Commission has approved the transaction.
Morgan Stanley & Co. LLC, Perella Weinberg Partners and J.P. Morgan Securities LLC acted as financial advisors to Solventum, and James Hu and Aaron J. Meyers of Cleary Gottlieb Steen & Hamilton acted as legal advisor to Solventum. Hal J. Leibowitz and Andrew R. Bonnes of Wilmer Cutler Pickering Hale and Dorr LLP acted as legal counsel and Wells Fargo Securities, LLC acted as exclusive financial advisor to Thermo Fisher. Solventum expects the transaction to be neutral to 2025 EPS and expects an estimated $3.4 billion in net proceeds, which it intends to use primarily to pay down debt. Andrew Bab and Sarah Jacobson of Debevoise & Plimpton is advising J.P. Morgan Securities as financial advisor to Solventum.
Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Purification Business of Solventum Corporation for approximately $4 billion on September 2, 2025. With the transaction complete, the business, which is now Thermo Fisher’s Filtration and Separation business, is part of the Life Sciences Solutions segment. Filtration and Separation colleagues will join Thermo Fisher. Axinn, Veltrop & Harkrider LLP, Latham & Watkins LLP and Hogan Lovells US LLP acted as legal advisor and Wells Fargo Corporation acted as financial advisor to Thermo Fisher. Reported Earnings • Aug 08
Second quarter 2025 earnings released: EPS: US$0.52 (vs US$0.51 in 2Q 2024) Second quarter 2025 results: EPS: US$0.52 (up from US$0.51 in 2Q 2024). Revenue: US$2.16b (up 3.8% from 2Q 2024). Net income: US$90.0m (up 1.1% from 2Q 2024). Profit margin: 4.2% (in line with 2Q 2024). Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. 공시 • Aug 08
Solventum Corporation Increases Earnings Guidance for Full Year 2025 Solventum Corporation increased earnings guidance for full year 2025. For the year, the company expected organic sales growth range to +2.0% to +3.0% (+2.5% to +3.5% excluding ~50 bps of SKU exit impact); from prior range of +1.5% to +2.5%. 공시 • Jul 18
Solventum Corporation to Report Q2, 2025 Results on Aug 07, 2025 Solventum Corporation announced that they will report Q2, 2025 results After-Market on Aug 07, 2025 공시 • Jun 10
Solventum Launches Preassembled, See-Through Vh2o2 Test Pack for Low-Temp Medical Instrument Sterilization Solventum announced the launch of its Attest™? Super Rapid Vaporized Hydrogen Peroxide (VH2O2) Clear Challenge Pack. The ready-to-use test integrates two previously FDA-cleared indicators - a biological indicator (BI) for confirming microbial neutralization and a chemical indicator (CI) for verifying proper sterilizer function - into a single-use test pack with a transparent container. Medical instrument sterility is a critical component in the fight against hospital-associated infections, which impact one in every 31 hospital patients in the U.S.4 The practice of every load monitoring - using dual indicators (both BIs and CIs) to verify the efficacy of every sterilization cycle for each batch of instruments - is recommended by industry guidelines and expert consensus to help minimize patient safety risks. This unique combination makes the Attest™? Super Rapid VH2O2 Clear Challenge Pack the first and only preassembled VH2O2 test pack that is U.S. FDA-cleared for routine monitoring across multiple sterilizer brands, models and cycle types, offering: Convenience: preassembled, ready-to-use pack eliminates the step of assembling testing pouches with separate indicators, saving time and mitigating the risk of errors inherent to manual preparation, like incorrect indicator placement or omission of an indicator. Accuracy: engineered to more accurately simulate the environment within a wrapped set of surgical instruments during a VH2O2 cycle.5 This helps to provide a realistic challenge to the sterilizer's ability to neutralize potentially harmful microorganisms, providing greater assurance that a "pass" result reflects effective steril penetration and conditions within the load. Simplification: integrated, all-in-one design helps streamline inventory management by reducing the need to order BIs, CIs and peel pouches individually. Reported Earnings • May 09
First quarter 2025 earnings released: EPS: US$0.79 (vs US$1.37 in 1Q 2024) First quarter 2025 results: EPS: US$0.79 (down from US$1.37 in 1Q 2024). Revenue: US$2.07b (up 2.7% from 1Q 2024). Net income: US$137.0m (down 42% from 1Q 2024). Profit margin: 6.6% (down from 12% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.0% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. 공시 • May 09
Solventum Corporation Revises Earnings Guidance for Full Year 2025 Solventum Corporation revised earnings guidance for full year 2025. For the period, the company expects Increased Organic sales growth range to +1.5% to +2.5% (+2.0% to +3.0% excluding 50 bps of SKU exit impact) from prior range of +1.0% to +2.0%. New Risk • May 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (3.0x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Profit margins are more than 30% lower than last year (5.8% net profit margin). 공시 • Apr 18
Solventum Corporation to Report Q1, 2025 Results on May 08, 2025 Solventum Corporation announced that they will report Q1, 2025 results After-Market on May 08, 2025 Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to €56.00, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Medical Equipment industry in Germany. Simply Wall St's valuation model estimates the intrinsic value at €84.49 per share. 공시 • Mar 27
Solventum Corporation, Annual General Meeting, Apr 30, 2025 Solventum Corporation, Annual General Meeting, Apr 30, 2025. Location: proxy United States 공시 • Mar 20
Solventum Corporation Provides Earnings Guidance for the Fiscal Year 2025 Solventum Corporation provided earnings guidance for the fiscal year 2025. For the year, the company reaffirmed its fiscal year 2025 guidance, originally provided in connection with its Fourth quarter earnings. 공시 • Mar 12
Solventum Launches Attest eBowie-Dick Test System Revolutionizing Sterilization Assurance Solventum announced the launch of the Attest™? eBowie- Dick Test System (eBowie- Dick System), an electronic test card and auto- reader for sterilization testing that eliminates the need for visual interpretation of results and manual documentation. In less than five seconds, the eBowie- Dick System's simple "pass" or "fail" digital display provides definitive test results and creates an automated record that can be integrated into a hospital's instrument tracking system, eliminating the need to scan analog test results. Traditional tests for steam dynamic-air removal sterilizers use a color-changing ink indicator to evaluate the efficacy of air removal and detect leaks in the sterilizer. The ink indicator is tucked between layers of a paper packet. The paper is discarded when the ink indicator is removed from the packet to assess the test results. The eBowie-Dick Test System can reduce the paper waste from Bowie- Dick tests entering a hospital's waste stream by 94% compared to paper waste generated by traditional Bowie- Dick Test Packs. The eBowie- Dick System is now available in the United States from authorized distribution partners and will roll out globally throughout 2025. Buy Or Sell Opportunity • Mar 02
Now 21% undervalued Over the last 90 days, the stock has risen 15% to €78.50. The fair value is estimated to be €99.31, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 1.2% per annum. Earnings are also forecast to grow by 20% per annum over the same time period. Reported Earnings • Feb 28
Full year 2024 earnings released Full year 2024 results: EPS: US$2.77. Revenue: US$8.25b (flat on FY 2023). Net income: US$479.0m (down 64% from FY 2023). Profit margin: 5.8% (down from 16% in FY 2023). Revenue is forecast to grow 1.3% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. 공시 • Feb 28
Solventum Corporation Provides Earnings Guidance for First Quarter of 2025 and Full Year 2025 Solventum Corporation provided earnings guidance for first quarter of 2025 and full year 2025. First Quarter is the expected low point for both operating margins and earnings per share with improvement through the balance of the year. The company anticipates First Quarter results will be the quarter most impacted by both foreign exchange headwinds and timing of spend. When coupled with the expected pace of increased restructuring savings through 2025.
Solventum is providing its full-year 2025 guidance- Organic sales growth of +1.0% to +2.0% (+1.5% to +2.5% excluding ~50bps of SKU Exit impact). 공시 • Jan 31
Solventum Corporation to Report Q4, 2024 Results on Feb 27, 2025 Solventum Corporation announced that they will report Q4, 2024 results After-Market on Feb 27, 2025 공시 • Jan 09
Trian Fund Management Issues an Open Letter to Shareholders of Solventum Corporation On January 8, 2025, Trian Fund Management, L.P. released an open letter and slide deck outlining its views on performance and opportunities for value creation ahead of Solventum Corporation’s expected Long Range Plan (LRP) announcement in February. In the letter, Trian Fund Management stated that despite performance declines since spinning out of 3M, Trian Fund Management expressed its views that the Company has potential to drive significant improvements as a standalone Company. Trian Fund Management also stated that if the Company can restore performance to historical levels, Trian Fund Management views the Company’s shares could be worth $140 by year-end 2027 vs. its $69 share price. Trian Fund Management expressed its view that the Company can further enhance value creation through improved operating performance, portfolio actions and prudent capital allocation. 공시 • Nov 14
Solventum Launches First 3D Printed Aligner Attachments to Revolutionize Aligner Treatment Solventum officially launched an anticipated innovation in aligner treatment, 3M Clarity Precision Grip Attachments. Available exclusively with 3M Clarity Aligners, Clarity Precision Grip Attachments are designed to solve one of the biggest challenges with aligner treatment - creating durable, accurately shaped, stain resistant attachments. Clarity Precision Attachments are poised to change aligner treatment, because they eliminate the technique sensitive, time-consuming attachment creation process that can introduce variability into treatment. Misplaced and malformed attachments resulting from the conventional approach can produce different forces than predicted in a treatment plan. In contrast, Clarity Precision Grip Attachments are accurately positioned, precisely shaped and designed to reduce this risk. Further, the procedure for Clarity Precision Grip Attachment eliminates the risk that an overfilled template results in residual cured composite flash on the tooth. Composite flash may attract stains, harbor plaque and exhibit engagement between the aligner and attachment. Because the procedure relies on alternative bonding agents, Clarity Precision Grip Attachments eliminate the risk of composite flash creation. The 3D printing manufacturing approach for Clarity Precision Grip Attachments lends other benefits to the product offering. The resulting attachments are customized to the fit each patient's unique tooth anatomy, and the combination of inorganic filler and organic resin, paired with post-processing techniques ensure that the 3D printed attachments are durable and more stain resistant than leading composites used with current attachment procedures. Clarity Precision Grip Attaching can be added to Clarity Aligners cases on Oral Care Portal. Previewed in 2024 at the AAO, 3M Clarity Precision Grip Attachments are available now in the United States and Canada. Additional global regulatory submissions and approvals are pending. Reported Earnings • Nov 08
Third quarter 2024 earnings released Third quarter 2024 results: EPS: US$0.70. Revenue: US$2.08b (flat on 3Q 2023). Net income: US$122.0m (down 74% from 3Q 2023). Profit margin: 5.9% (down from 22% in 3Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. 공시 • Nov 08
Solventum Corporation Revises Earnings Guidance for the Year 2024 Solventum Corporation revised earnings guidance for the year 2024. The company now expects organic sales growth to the upper half of 0% to +1.0% (previously 0% to +1.0%). 공시 • Oct 25
Solventum Reportedly Explore Sale of Filtration Unit Solventum Corporation (NYSE:SOLV) has retained bankers to explore a sale of its purification and filtration business, according to people familiar with the matter. The business is expected to attract takeover interest from strategic and private-equity buyers. 공시 • Oct 15
Solventum Corporation to Report Q3, 2024 Results on Nov 07, 2024 Solventum Corporation announced that they will report Q3, 2024 results After-Market on Nov 07, 2024 공시 • Oct 10
Solventum Corporation Appoints Dr. Ryan Egeland, MD as Chief Medical Officer Solventum announced that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group president, Medical Surgical, Solventum. Dr. Egeland joins Solventum from Crossfire Medical, where he has been Chief Executive Officer since 2022. Previously, he served as the Head of Strategic Ventures and Chief Medical Officer for Cardiovascular Systems Inc. (CSI). Prior to his tenure at CSI, Dr. Egeland led teams in Business Development & Licensing, Medical & Scientific Affairs, and Product Marketing at Medtronic, Covidien, and ev3. Dr. Egeland earned his M.D. from Harvard Medical School and was a Rhodes Scholar at the University of Oxford, where he completed his Ph.D. and M.B.A. He trained in plastic and reconstructive surgery at Northwestern Memorial Hospital and has worked in major academic hospitals and private clinics. He is a Board Member of Piraeus Medical and Vergent Bioscience. 공시 • Sep 23
Solventum Corporation(NYSE:SOLV) dropped from FTSE All-World Index (USD) Solventum Corporation(NYSE:SOLV) dropped from FTSE All-World Index (USD) 공시 • Aug 09
Solventum Corporation Raises Earnings Guidance for Full Year 2024 Solventum Corporation raised earnings guidance for its full-year 2024. For the period, Company expects Organic sales growth of 0% to +1.0% (previously -2% to 0%). 공시 • Jul 23
Trian Fund Management Engages in Discussions with Solventum Corporation On July 23, 2024, Nelson Peltz's Trian Fund Management LP announced that on July 22, 2024, it has built a stake in 3M Company's spinoff Solventum Corporation sending shares of the Company up 3.4% after the bell. Trian Fund Management stated that it has reached out to the Company to discuss ways to unlock shareholder value as it believes the Company should re-accelerate organic growth, restore margins, and consider asset sales. Trian Fund Management expressed its views that the Company has a significant value creation opportunity as a standalone public company. Trian Fund Management added that it looks forward to engaging constructively with the Company’s management and board. 공시 • Jul 16
Solventum Corporation to Report Q2, 2024 Results on Aug 08, 2024 Solventum Corporation announced that they will report Q2, 2024 results After-Market on Aug 08, 2024 공시 • Jun 24
Solventum Corporation Introduces Denials Prevention Solution, an AI-Powered Tool, Empowering Health Systems to Help Reduce Write-Offers and Improve Top Line Revenue Solventum Corporation announced a new artificial intelligence (AI)-driven payment integrity and revenue cycle solution, Solventum Revenue Integrity System. In collaboration with Sift Healthcare, this solution is designed to help health systems not only reduce potential denials but prevent them and ensure timely and accurate payer reimbursement. With tight margins and reduced resources, claim denials from payers are a persistent challenge across the healthcare industry, leading to significant revenue loss and increased administrative costs. Healthcare organizations cited claim denials as the greater revenue cycle management challenge, with more than half of responders (58%) giving it a top rank, followed by "specific payer challenges" (44%), staffing (41%) and cost of collections (26%). Targeting clinical documentation integrity (CDI), coding and utilization review workflows, Solventum aims to transform denials prevention by integrating machine learning-based interventions, coding and prebill validation into the front end of the healthcare revenue cycle. With this technology, healthcare providers are empowered to optimize payment outcomes by predicting reimbursement at every step of the patient's clinical journey. Functioning as an integrated artificial intelligence (AI) agent within clinical workflows, Solventum Revenue Integrity provides health systems with near real time insights into reimbursement likelihoods and offer strategic, compliant and actionable recommendations for intervention. The Solventum Revenue Integrity solution complements Solventum's existing suite of healthcare information system software that supports the entire journey, from the first patient visit to the final payment. Reported Earnings • May 10
First quarter 2024 earnings released: EPS: US$1.37 (vs US$1.70 in 1Q 2023) First quarter 2024 results: EPS: US$1.37 (down from US$1.70 in 1Q 2023). Revenue: US$2.02b (flat on 1Q 2023). Net income: US$237.0m (down 19% from 1Q 2023). Profit margin: 12% (down from 15% in 1Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 7.0% growth forecast for the Medical Equipment industry in Germany. 공시 • May 10
Solventum Corporation Reaffirms Earnings Guidance for Its Full-Year 2024 Solventum Corporation reaffirmed earnings guidance for its full-year 2024. For the period, Company expects Organic revenue growth of -2% to 0%. 공시 • Apr 24
Solventum Corporation to Report Q1, 2024 Results on May 09, 2024 Solventum Corporation announced that they will report Q1, 2024 results at 9:30 AM, US Eastern Standard Time on May 09, 2024 